Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
企業コードMRVI
会社名Maravai LifeSciences Holdings Inc
上場日Nov 20, 2020
最高経営責任者「CEO」Mr. Bernd Brust
従業員数570
証券種類Ordinary Share
決算期末Nov 20
本社所在地10770 Wateridge Circle Suite 200
都市SAN DIEGO
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号92121
電話番号18585460004
ウェブサイトhttps://www.maravai.com/
企業コードMRVI
上場日Nov 20, 2020
最高経営責任者「CEO」Mr. Bernd Brust
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし